Related Experiment Video

Updated: Aug 7, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

Pharmacological interventions for the treatment of neonatal jaundice

Phyllis A Dennery1

  • 1Department of Neonatal and Developmental Medicine, Stanford University, 750 Welch Road, Suite315, Palo Alto, CA 94304, USA. dennery@stanford.edu

Seminars in Neonatology : SN
|September 5, 2002
PubMed

Insights

Neonatal hyperbilirubinaemia management is improving with novel pharmacological agents. Metalloporphyrins show promise in inhibiting bilirubin production, offering a new treatment for infant jaundice.

Area of Science:

  • Neonatal Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Neonatal hyperbilirubinaemia stems from increased bilirubin production and reduced elimination.
  • Current treatments primarily rely on phototherapy, with limited pharmacological options.
  • Understanding bilirubin metabolism pathways is crucial for developing new interventions.

Purpose of the Study:

  • To explore novel pharmacological interventions for neonatal hyperbilirubinaemia.
  • To evaluate the potential of metalloporphyrins in treating infant jaundice.
  • To assess the safety and efficacy of new therapeutic agents.

Main Methods:

  • Review of existing literature on pharmacological agents for hyperbilirubinaemia.
  • Analysis of recent clinical trials involving metalloporphyrins.
  • Investigation of heme catabolism inhibition as a treatment strategy.

Main Results:

  • Metalloporphyrins demonstrate potential by inhibiting heme catabolism and bilirubin production.
  • Previously studied agents like D-penicillamine, phenobarbital, and clofibrate warrant further investigation.
  • Phototherapy remains the primary treatment, but new pharmacological avenues are emerging.

Conclusions:

  • Metalloporphyrins represent a novel pharmacological approach for neonatal jaundice.
  • Further research is essential to confirm the safety and efficacy of these new therapies.
  • Pharmacological interventions could complement or enhance current treatment protocols for infant jaundice.

More Related Videos

Isolation of Neonatal Extrahepatic Cholangiocytes07:54

Isolation of Neonatal Extrahepatic Cholangiocytes

Published on: June 5, 2014

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers09:36

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Published on: July 28, 2022

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...